Everolimus loaded NPs with FOL targeting: preparation, characterization and study of its cytotoxicity action on MCF-7 breast cancer cell lines
DOI:
https://doi.org/10.35516/jjps.v15i1.286Keywords:
Breast cancer, PLGA NPs, MCF-7, Everolimus, mTOR inhibitorsAbstract
Background and objective: The mortality cases of breast cancer (BC) are probably caused by inadequate of the benefits of treatment and early detection, moreover the lack of appropriate facilities for diagnosis and detection, also high cost effective of the treatment. The preparation of Everolimus (EV) loaded PLGA-TPGS NPs (nano-EV) targeting with folate (PLGA-TPGS-EV-FOL) and investigate their toxicity effect on human MCF-7 BC cell lines may be given an appropriate lines in BC treatment. Methods: EV loaded NPs were prepared by combination of sonication and emulsification/solvent evaporation method with slight modifications into four formulations A, B, C , and D. EV loaded NPs were characterized by FESEM and TEM for particle size (PS) and zeta potential (ZP), FT-IR, drug loading (DL%), encapsulation efficiency (EE%), In vitro drug release, inhibition concentration IC50 and cell viability%, apoptosis, angiogenesis, glucose transporting, and HIF-1A mRNA gene expression. Results: Formulation B of EV loaded NPs was found to be lowest PS 100±12.7 nm, PDI 0.152, and have ZP, -23.2.5. The higher DL% content of EV was detected as 7.32±1.1% and EE% was 87± 2.6% in formulation B. The results suggested that the free EV dissolution was 80% within 4h but release profile of A, B, C, and D formulations within 4h were 34, 23, 26, 30%, respectively. EV formulated in NPs showed better effects against the MCF-7 BC cell line than EV free and EV loaded NPs formulation B achieved even better therapeutic effect than A, C, and D formulations. HIF-1A mRNA gene expression was decreased when treated the MCF-7 BC cells with EV loaded NPs formulation B compare to expression in untreated cells. Conclusion: EV loaded NPs may be useful in lowering the cost of treatment and may be involved in the decline of chemotherapy side effects.
References
Lauby-Secretan, B, Scoccianti, C, Loomis, D, Benbrahim-Tallaa, L., Bouvard, V, Bianchini, F, Straif, K). Breast-Cancer Screening-Viewpoint of the IARC Working Group. The New England Journal of Medicine, 2015;372, 2353-2358.
Porter P. Westernizing women’s risks? Breast cancer in lower-income countries. New Eng J of Med. 2008; 358: 213-216.
Hans M and Lowman A. Biodegradable nanoparticles for drug delivery and targeting, Curr. Opin. Solid State Mater. Sci. 2002; 6 319–327.
Hillaireau H, and Couvreur P). Nanocarriers' entry into the cell: relevance to drug delivery, Cell. Mol. Life Sci. 2009; 66, 2873–2896.
Xiangjun Han, Ke Xu, Olena Taratula, Khashayar Farsad. Applications of nanoparticles in biomedical imaging. Nanoscale, 2019; 11 (3) , 799-819.
Fabienne D et al. PLGA-based nanoparticles: An overview of biomedical applications. Journal of Controlled Release. 2012; 161 .p505–522.
Sadoqi, M. ,Lau-Cam, C.A., Wu, S.H Investigation of the micellar properties of the tocopheryl polyethylene glycol succinate surfactants TPGS 400 and TPGS 1000 by steady state fluorometry. J. Colloid Interface Sci.2009; 333:585–589.
Ma Y, Zheng Y, Liu K, Tian G, Tian Y, Xu L, et al. Nanoparticles of poly (lactide-co-glycolide)-da-tocopheryl polyethylene glycol 1000 succinate random copolymer for cancer treatment. Nanoscale Res Lett; 5: 2010; 1161.
Marin, T.M., Keith, K., Davies, B., et al., Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J. Clin. Invest. 2011; 121, 1026–1043.
Wullschleger S, Loewith R, Hall MN TOR signaling in growth and metabolism. Cell. 2006; 124:471–84.
Mohammad J and Saad M. Nano-encapsulation and characterization of baricitinib using poly-lacticglycolic acid co-polymer. Saudi Pharmaceutical Journal, 2019; 27, 491–501.
Joshi G, Kumar A, Sawant K. Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles. Drug Del. 2016; 23 (9), 3492–3504.
Félix RP, Jonker AM, Wolke JG et al. Physicochemical Properties and Applications of Poly (lactic-co-glycolic acid) for Use in Bone Regeneration. Tissue Eng Part B.2013; 19:380–390.
Feczkó T, Tóth J, Dósa G, Gyenis J. Influence of process conditions on the mean size of PLGA nanoparticles. Chemical Engineering and Processing: Process Intensification. 2011; 50: 846-853.
Nance EA, Woodworth GF, Sailor KA, Shih TY, Xu Q, et al.). A dense poly (ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci Transl Med, 2012; 4: 149.
Janes, K.A.; Calvo, P.; Alonso, M.J). Polysaccharide colloidal particles as delivery systems for macromolecules. Adv. Drug Deliv. Rev., 2001; 47, 83–97.
Yuandong Ma et al. Nanoparticles of Poly (Lactide-Co-Glycolide)-d-a-Tocopheryl Polyethylene Glycol 1000 Succinate Random Copolymer for Cancer Treatment. Nanoscale Res Lett. 2010;5: 1161–1169.
Shuqian W, Long Z, Yunyun Q, Kun W. Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy. R Soc Open Sci.; 2018; 5(11): 181457.
Duan X, Xiao J, Yin Q,et al. Multi-targeted inhibition of tumor growth and lung metastasis by redox-sensitive shell crosslinked micelles loading disulfiram. Nanotechnology, 2014; 25(12): 125102.
Liu P, Brown S, Channathodiyil P, et al. Reply: Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. British Journal of Cancer, 2013; 108: 994.
Ma Y et al. Nanoparticles of Poly(Lactide-Co-Glycolide)-d-a-Tocopheryl Polyethylene Glycol 1000 Succinate Random Copolymer for Cancer Treatment. Nanoscale Res Lett ,2010; 5:1161–1169.
Maleki H et al. Methotrexate-Loaded PLGA Nanoparticles: Preparation, Characterization and their Cytotoxicity Effect on Human Glioblastoma U87MG Cells. Int J Med Nano Res, 2017; 4: 20.
Fonseca C, Simoes S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: Preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release , 2002; 83: 273-286.
Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA; 2003; 100:3983–8.
Hamzah H. Kzar, Moshtak A. wtwt, Moaed E. Al-Gazally. Study the Glucose Transport, Angiogenesis and Apoptosis Behavioral through Chemotherapy Treatment According to Receptors Status in Women with Breast Cancer. Indian Journal of Forensic Medicine & Toxicology, 2020;14(3): 2555-2559.
Golias, T.; Papandreou, I.; Sun, R.; Kumar, et al. Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours. Sci. Rep. 6, 31146.
Haider O. Mossa Al-Gazali, Hamzah H. Kzar , Moshtak A. Wtwt , Moaed E. Al-Gazally.. EV Targeting MCF-7 Breast Cancer Cell Lines Inhibit Both mTOR and HIF-1A: Molecular Docking Study. Medico Legal Update, 2021; 21(1): 1367-1373.
Georgina N, et al. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharmaceutica Sinica 2015;B;5(5):378–389.
Sara Khlefat and Sanaa Bardaweel. Celecoxib inhibits cancer growth through cyclooxygenase 2 (COX2) independent pathways in HepG2 hepatocellular carcinoma. Jordan Journal of Pharmaceutical Sciences; 2021; 14(4): 487-504.
Hana R. Bajes and Emad A S Al-Dujaili. Probiotics and Biotechnology Advances in Reducing and Preventing Colorectal Cancer; Minireview. Jordan Journal of Pharmaceutical Sciences; 2019;12(3): 39-49.
Qosay A, Nizar A, Katreen B, Mohammad H, Ghazi A , Ammar A. Design, Synthesis and Biological Evaluation of Potential Novel Zinc Binders Targeting Human Glyoxalase-I; A Validated Target for Cancer Treatment. Jordan Journal of Pharmaceutical Sciences; 2018;11(1): 25-37.
